Elobixibat-d5

Elobixibat-d5 is the deuterium labeled Elobixibat (HY-15790) . Elobixibat (A 3309; AZD 7806) is orally active, bile acid transporter (IBAT) inhibitor with IC50 values ??of 0.53 nM (human IBAT), 0.13 nM (mouse IBAT), and 5.8 nM (canine IBAT) . Elobixibat can lower LDL cholesterol, increase serum GLP-1, promote colonic motility, and has the potential to treat metabolic syndrome. Elobixibat can be used in the study of chronic functional constipation (CIC), dyslipidemia, non-alcoholic hepatitis, and liver tumors in the elderly[1][2][3][4].

Product Specifications

Product Name Alternative

A 3309-d5; AZD 7806-d5

UNSPSC

12352005

Target

Apical Sodium-Dependent Bile Acid Transporter; Isotope-Labeled Compounds

Related Pathways

Membrane Transporter/Ion Channel; Others

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology; Cancer

Smiles

O=C(COC(C=C1C(N(CC(CCCC)(CCCC)CS1(=O)=O)C2=C([2H])C([2H])=C([2H])C([2H])=C2[2H])=C3)=C3SC)N[C@@H](C(NCC(O)=O)=O)C4=CC=CC=C4

Molecular Formula

C36H40D5N3O7S2

Molecular Weight

700.92

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Wong BS, et al. Elobixibat for the treatment of constipation. Expert Opin Investig Drugs. 2013 Feb; 22 (2) :277-84.|[3]Sugiyama Y, et al. Impact of elobixibat on liver tumors, microbiome, and bile acid levels in a mouse model of nonalcoholic steatohepatitis. Hepatol Int. 2023 Dec;17 (6) :1378-1392.|[4]Yamauchi R, et al. Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. Hepatol Int. 2021 Apr;15 (2) :392-404.